FindTrial
Sign In

Baseline Treatment

OTHER9 trials

Sponsors

Hoffmann-La Roche, University of Faisalabad, Riphah International University, London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's

Conditions

Autism Spectrum Disorder (ASD)Cerebral PalsyConstipationDisability PhysicalForward Head PostureIntellectual DisabilityLow Back PainMild Cognitive Impairment

Phase 3

Efficacy and Safety Study of Satralizumab (SA237) as Add-on Therapy to Treat Participants With Neuromyelitis Optica (NMO) and NMO Spectrum Disorder (NMOSD)
CompletedNCT02028884
Hoffmann-La RocheNeuromyelitis Optica (NMO), NMO Spectrum Disorder (NMOSD)
Start: 2014-02-20End: 2021-12-23Updated: 2023-04-18

Unknown Phase

Comparing the Effects of Pilates and McKenzie in Power Looms Workers Having Nonspecific Chronic Low Back Pain
CompletedNCT05473416
University of FaisalabadDisability Physical, Nonspecific Chronic Low Back Pain, Pain
Start: 2022-08-15End: 2022-12-24Updated: 2023-12-05
Effects of Balance Training Exercises on Mobility in Open and Closed Environment in Children With Visual Impairments.
CompletedNCT05787223
Riphah International UniversityVisual Impairment
Start: 2023-03-09End: 2023-08-30Updated: 2023-12-27
Effects of Cervical Spine Retraction Exercise With and Without Diaphragmatic Breathing in Forward Head Posture.
NCT06130969
Riphah International UniversityForward Head Posture
Start: 2023-05-10End: 2024-02-10Target: 52Updated: 2023-12-27
Effect of Transcutaneous Electrical Stimulation on Constipation
CompletedNCT06198244
Riphah International UniversityCerebral Palsy, Constipation
Start: 2023-12-01End: 2024-02-05Updated: 2024-06-13
Effects of Diaphragm Manual Therapy Verses Sustained Natural Apophyseal Glide in Mechanical Neck Pain
CompletedNCT06460532
Riphah International UniversityNeck Pain
Start: 2024-06-30End: 2024-10-10Updated: 2024-10-15
Comparison of Egoscue Versus Pilates Exercises in Patient With Mechanical Low Back Pain
CompletedNCT06461494
Riphah International UniversityLow Back Pain
Start: 2024-06-30End: 2024-10-10Updated: 2024-10-15
Effects of Shuttle Balance Training on Balance , Gait and Postural Control in Children With Mild Cognitive Impairment
RecruitingNCT06974890
Riphah International UniversityMild Cognitive Impairment
Start: 2025-04-15End: 2025-07-10Target: 24Updated: 2025-05-16
A Cognitive Behavioral Therapy Approach to Addressing Anxiety in Children With ASD and Intellectual Disability
Not yet recruitingNCT07245160
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph'sAutism Spectrum Disorder (ASD), Intellectual Disability
Start: 2025-12-01End: 2026-12-31Target: 24Updated: 2025-11-24

Related Papers

Long-Term Efficacy and Safety of Satralizumab in Patients With Neuromyelitis Optica Spectrum Disorder From the SAkuraMoon Open-Label Extension Study.
2025-07-311 citations
Analysis of infection rates in neuromyelitis optica spectrum disorder: Comparing satralizumab treatment in SAkuraMoon, post-marketing, and US-based health claims data.
2025-04-191 citations
Immunogenicity dynamics and covariate effects after satralizumab administration predicted with a hidden Markov model
CPT Pharmacometrics & Systems Pharmacology2024-10-083 citations
Safety and Effectiveness of Satralizumab in Japanese Patients with Neuromyelitis Optica Spectrum Disorder: A 6-month Interim Analysis of Post-marketing Surveillance.
2024-07-165 citations
Real-world management of patients with neuromyelitis optica spectrum disorder using satralizumab: Results from a Japanese claims database.
2024-02-1211 citations
Long-term Efficacy of Satralizumab in Adults with Aquaporin-4-IgG-seropositive (AQP4-IgG+) Neuromyelitis Optica Spectrum Disorder (NMOSD): Results from SAkuraMoon (S5.001)
Neurology2023-04-251 citations
Long-term Safety of Satralizumab in Adults with Aquaporin-4-IgG-seropositive (AQP4-IgG+) Neuromyelitis Optica Spectrum Disorder (NMOSD): Results from SAkuraMoon (P13-5.002)
Neurology2023-04-25
SAkuraBONSAI: Protocol design of a novel, prospective study to explore clinical, imaging, and biomarker outcomes in patients with AQP4-IgG-seropositive neuromyelitis optica spectrum disorder receiving open-label satralizumab
Frontiers in Neurology2023-02-176 citations
Long-term Efficacy of Satralizumab in AQP4-IgG-Seropositive Neuromyelitis Optica Spectrum Disorder From SAkuraSky and SAkuraStar.
2022-12-0837 citations
Long-term safety of satralizumab in neuromyelitis optica spectrum disorder (NMOSD) from SAkuraSky and SAkuraStar
Multiple Sclerosis and Related Disorders2022-07-0556 citations
Quantifying the relationship between disability progression and quality of life in patients treated for NMOSD: Insights from the SAkura studies.
2021-10-159 citations
Antibodies to watch in 2020.
2020-01-01328 citations
Trial of Satralizumab in Neuromyelitis Optica Spectrum Disorder
New England Journal of Medicine2019-11-27603 citations